Company ProfilePremium

AiLife International Group Limited (formerly Ling Yui Holdings Limited)

Company Profile Analysis

Ticker: 0784.HK愛生命國際集團有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
AiLife International Group Limited - Company showcase

Year Founded & Workforce

2000

74 Employees

AiLife International Group Limited logo

AiLife International Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AiLife International Group Limited Overview

AiLife International Group Limited is, in operating terms, still the business historically known as Ling Yui: a small Hong Kong foundation-engineering contractor that performs excavation and lateral support (ELS), pile cap and pile construction, site formation and ancillary road and drainage works, overwhelmingly for private-sector developments and usually for main contractors. With FY2026 revenue of HK$179.3 million, a loss of HK$11.4 million, 74 employees and equity of HK$45.5 million, it is a micro-cap participant in a fragmented, price-competitive and cyclical local market that has been depressed by high interest rates and weak private-residential development. The April 2026 acquisition of 70.02% by Hapbiotech — a vehicle of Shenzhen genomics and liquid-biopsy group HaploX — followed by the rebrand to "AiLife" and the appointment of HaploX's two founders as executive directors, signals a probable strategic pivot towards AI-enabled life sciences. No such transaction has yet been announced, so the equity now trades largely on change-of-control optionality rather than on construction fundamentals.


Company's own description (paraphrased from the FY2026 Annual Report)

The FY2026 Management Discussion and Analysis characterises the Group as a Hong Kong-based main contractor that principally provides foundation works — namely excavation and lateral support works, pile cap works and pile construction — plus site formation works and ancillary services such as road and drainage works, for foundation projects in the private sector. The Group reports a single operating segment: the provision of foundation engineering services. All revenue-generating operations and borrowings are denominated in Hong Kong dollars.

At IPO in 2017 the Group described itself as a subcontractor working mainly through Ming Lee Foundation for main contractors of private foundation projects, undertaking specific parts of foundation work designated by the main contractor (Prospectus, 2017; Ipsos). The shift in self-description from "subcontractor" (2017) to "main contractor" (2025–2026 reports) reflects the Group's stated objective of obtaining additional qualifications to tender directly as a main contractor; Ming Lee Engineering Company Limited holds an authorised-signatory registration in the Foundation category (senior management bio of Mr. Lo Hin Chi, FY2026 AR).

Business model and revenue model

Revenue model: ~100% project-based construction contract revenue recognised over time (HKFRS 15). There is no subscription, licensing or recurring service income. Minor "other income" lines include sale of waste material, machinery rental income, gains on equipment disposal, interest and compensation (HK$3.8M in FY2026 vs HK$0.7M in FY2025).

Product vs service mix: Effectively 100% services (construction works). Not publicly disclosed as a percentage split, but the single-segment disclosure makes the characterisation unambiguous.

Cost structure: Direct costs (subcontracting, labour, materials, machinery depreciation and fuel) represented ~92% of revenue in FY2026 (HK$165.7M of HK$179.3M). Administrative expenses were HK$26.6M. Total staff costs (incl. directors and MPF) were HK$35.6M.

Asset base: The Group owns machinery and construction equipment (e.g., excavators with hydraulic hammers and telescopic arms per aggregator description); machinery with net book value of HK$9.0M was pledged to banks and a financial institution at 31 Mar 2026 (HK$11.9M at 31 Mar 2025).

Working-capital intensity: Contract assets, retention receivables and trade receivables are large relative to revenue, which is why the expected-credit-loss (ECL) charge of HK$22.2M in FY2025 was decisive for that year's loss.

Value-chain position

In Hong Kong's construction chain (developer → main contractor → specialist/foundation contractor → sub-subcontractors/labour), Ling Yui sits at the specialist-foundation layer. It wins work either as subcontractor to the main contractor engaged by the developer or, increasingly, as foundation main contractor where the developer lets the foundation package separately. It in turn engages subcontractors and suppliers (steel, concrete, machinery rental) and bears responsibility for their performance.

Customer types and end-markets

Customers: Main contractors engaged by property developers; property developers directly for foundation packages; the FY2026 chairman's statement indicates a new project team targeting "prominent clients" and the public foundation sector as a potential growth avenue.

End-markets: Private residential and commercial property development in Hong Kong (dominant); public works (aspirational).

Concentration: The company lists as a principal risk that a significant portion of revenue comes from non-recurring contracts awarded by a few customers.

Independent characterisation

Ling Yui is a sub-scale, single-market, single-segment cyclical contractor whose fortunes track Hong Kong private-sector land sales and foundation starts with a lag of 6–18 months. Gross margins have swung from 22.8% (FY2017) to –2.8% (FY2023) and back to 14.4% (FY2025) before falling again to 7.6% (FY2026), illustrating very limited pricing power. Since April 2026 the listed company's strategic identity is in flux: its new controller is a PRC genomics group, its name now references "AI" and "Life", and two genomics/AI scientists joined the board. Investors should therefore treat the construction business as the current earnings base and the potential injection or development of life-sciences activities as an unconfirmed option.

Strategy

Stated strategy themes (FY2026 Annual Report, paraphrased)

  1. Prudent project selection and credit control: Focus on customers with proven records of timely settlement, accepting lower volume.

  2. Cost control and prudent financial management amid a slow private property market and high interest rates.

  3. Upgrade qualifications and financial resources to tender as a main contractor in the private sector.

  4. Invest in manpower and information systems to improve capacity and efficiency.

  5. Broaden the client base toward the public foundation sector via a dedicated project team targeting prominent clients with sizeable pipelines.

  6. Leverage listed status to enhance reputation in the sector.

Strategic initiatives in the last 24 months

DateInitiativeDetailStatus
FY2026Credit-tightening programmeSelective customer engagement post-ECL chargeOngoing
FY2026Public-sector business development teamTargeting large clients in public foundation worksOngoing; no wins disclosed
26 Jun 2025Workforce Diversity PolicyGroup-wide inclusive workplace commitmentsAdopted
28 Aug 2025New M&A adoptedHybrid/electronic meetings, treasury shares, paperlessEffective
9 Apr 2026Change of control to HaploX vehicle70.02% acquired at HK$0.2375/shareCompleted
18 Jun 2026Rebrand to "AiLife International Group"New English/Chinese names, stock short name from 4 Aug 2026Effective
FY2026Climate targets vs FY2022 base yearGHG intensity reduction targets (gross, no offsets, not SBTi-validated)Ongoing

Medium-term financial targets / guidance

None. The company provides no numerical revenue, margin or return targets. Management's qualitative outlook is that conditions "will remain challenging" with intense pricing competition.

Post-takeover strategic direction (analyst assessment)

The appointment of HaploX's founders, the "AiLife" name and the controller's background in genomics, liquid biopsy and bioinformatics strongly suggest the new controller intends to use the listed shell to develop or inject AI-enabled life-sciences or health businesses. The FY2026 report, however, states that there were no plans for material investments or capital assets as at 31 March 2026, and no acquisition, disposal of the construction business, or very substantial acquisition has been announced as of 11 October 2026. Any reverse-takeover-like injection would be subject to HKEX's stringent new-listing-equivalent rules (Chapter 14 RTO provisions), a material gating factor.

Products & Services

All offerings fall within the single foundation-engineering segment. No pricing schedules are published; work is priced by competitive tender per project.

Flagship projects: Named projects on hand, contract values and order backlog for FY2026 were not publicly disclosed in the sources reviewed (the annual report MD&A excerpt reviewed did not list them).

Life-sciences / AI offerings: None currently.

Product Portfolio

Service lineDescriptionKey capabilities / specificationsTarget customerLaunch / statusPricing model

Excavation and lateral support (ELS)

Excavation of basements/pits with temporary support (sheet piles, struts, walings) to retain soil and protect adjacent structures

Sheet piling, large-scale excavation; experience cited in chairman's bio

Main contractors and developers of private projects

Core since 2000

Lump-sum or re-measurement tender

Pile construction

Installation of piles to transfer building loads to bearing strata

Aggregator profile cites large diameter bored piles, driven H-piles, pre-bored socket H-piles and mini-piles

Main contractors / developers

Core since 2000s

Tender

Pile cap works

Construction of reinforced-concrete caps linking pile groups to superstructure

Formwork, rebar, concreting

Main contractors

Core

Tender

Site formation

Earthworks, slope and level formation to prepare sites for construction

Earth-moving fleet

Developers / main contractors

Core

Tender

Road and drainage works

Ancillary civil works associated with foundation projects

Small-scale civil works

Same

Ancillary

Tender / variation orders

Machinery rental

Rental of owned machinery to third parties (recognised as other income)

Excavators and construction equipment

Other contractors

Recognised in FY2026

Rental rate

Sale of waste material

Sale of scrap/waste from sites (other income)

—

Recyclers

Recognised in FY2026

Spot

Financial Narrative

Basis: Audited consolidated statements, fiscal years ended 31 March. Figures from company filings unless flagged. "Agg." = aggregator-derived (TipRanks/ROIC.ai/Stoxray) and should be checked against the full annual report before reliance. Empty cells = not publicly disclosed in the sources reviewed.

Income statement

Notes: Direct costs for FY2022–FY2024 are derived as revenue minus gross profit. FY2026 D&A is ROIC.ai's rounded figure. FY2026 implied finance costs and other items (~HK$2.2M) cannot be separated from the extract reviewed.

Longer revenue history (context)

Sources: FY2018, FY2019, FY2022, FY2023, FY2025, FY2026 results; FY2017 gross profit derived from the 22.8% margin cited in FY2018 results; FY2017 profit derived from the 45.7% decline cited; FY2020 revenue per TipRanks.

Revenue CAGR: FY2022→FY2026 (4 years): approximately –15.0% p.a.; FY2021→FY2026 (5 years): approximately –5.7% p.a.; FY2017→FY2026 (9 years): approximately –2.2% p.a. (computed).

Balance sheet

Notes: Equity FY2022–FY2024 per ROIC.ai (rounded). Goodwill/intangibles inferred as nil because ROIC.ai tangible book value equals book value in every year. "Total debt" as defined by the company in the gearing calculation is substantially larger than bank borrowings (it likely includes lease liabilities, other loans and/or amounts due to related parties — the composition was not itemised in the extract reviewed).

Cash flow

ROIC.ai's rounded FCF per share implies roughly +HK$16M (FY2022), +HK$32M (FY2024) and –HK$16M (FY2025), each with ±HK$4M rounding error; TipRanks characterises recent operating and free cash flow as negative. The FY2026 report confirms no equity fund raising and no capital commitments.

Ratios

ROA, current ratio, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle cannot be calculated reliably without total assets, current liabilities, finance cost and receivable-day data — not publicly disclosed in sources reviewed. Net debt/EBITDA is in any case not meaningful in FY2025–FY2026 given negative or near-zero EBITDA.

Commentary on trends and drivers

Revenue. The Group's top line is lumpy and has been in structural decline since the FY2020 peak (HK$452.6M). FY2023's 30.6% drop reflected project delays and pandemic disruption; FY2024 fell a further 18.8% as Hong Kong's private development pipeline shrank under elevated HIBOR-linked borrowing costs. FY2025 recovered 10.5% to HK$214.5M, but management deliberately sacrificed volume in FY2026 (–16.4%) by restricting work to customers with sound payment records — a credit-control response to the FY2025 ECL hit. In other words, FY2026's revenue decline is partly self-imposed, an important nuance for anyone modelling recovery.

Gross margin. Margins have oscillated between –2.8% and 22.8% over a decade. The FY2023 gross loss reflected cost overruns and delays; FY2024–FY2025 margins of ~14–15% were the best since FY2018, but FY2026 margins halved to 7.6% because the Group accepted lower tender prices to keep its fleet and crews utilised. Management explicitly expects continued fierce price competition in the private foundation segment as rivals chase volume.

Operating costs. Administrative expenses are sticky at ~HK$27–28M, so the business needs roughly HK$200M+ of revenue at mid-teens gross margins just to break even at the operating line. FY2026 savings came from lower legal and professional fees (–HK$0.8M), lease depreciation (–HK$0.4M) and staff costs (–HK$0.3M).

Credit losses. The HK$22.2M ECL provision in FY2025 (≈10% of revenue) was the single largest swing factor and reveals the Group's exposure to counterparty stress among Hong Kong main contractors and developers.

Balance sheet. Equity has nearly halved in four years (HK$107M → HK$45.5M) through cumulative losses of ~HK$61M from FY2023 to FY2026. Positively, the Group repaid most bank borrowings (HK$25.0M → HK$2.3M) and reduced company-defined total debt from HK$75.0M to HK$41.3M, cutting gearing from 131.8% to 90.8%. Cash, however, fell to just HK$6.4M, which leaves little buffer for a business with large contract-asset balances.

Inflection. The investment case has inflected not on operations but on ownership: the HK$133M paid by Hapbiotech (HK$0.2375/share) was roughly 2.9x book value at the time, and the current market price (~HK$0.56) implies ~9.8x FY2026 book — a valuation that cannot be justified by the construction business alone.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

SegmentFY2024FY2025FY2026

Foundation engineering services revenue (HKD Mn)

194.0214.5179.3

Segment gross profit (HKD Mn)

28.631.013.6

Segment gross margin (%)

14.814.47.6

YoY revenue growth (%)

-18.810.5-16.4

% of total revenue

100100100

Group Entities

EntityRoleSource

AiLife International Group Limited (Cayman)

Listed holding company

FY2026 AR

Smart Sage (BVI, intermediate holding)

Holds Ming Lee Engineering (reorganisation 2017)

FY2019 results

Southern Sun (BVI, intermediate holding)

Holds Ming Lee Foundation (reorganisation 2017)

FY2019 results

Ming Lee Foundation Company Limited (HK)

Principal operating subsidiary; foundation works

FY2026 AR; prospectus

Ming Lee Engineering Company Limited (HK)

Operating subsidiary; registered in Foundation category

FY2026 AR

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (HKD Mn)

344.3239.0194.0214.5179.3

Revenue growth (%)

42.9-30.6-18.810.5-16.4

Direct costs (HKD Mn)

319.5245.6165.4183.5165.7

Gross profit (HKD Mn)

24.8-6.628.631.013.6

Gross margin (%)

7.2-2.814.814.47.6

Other income and net gains (HKD Mn)

———0.73.8

Administrative expenses (HKD Mn)

———28.326.6

ECL impairment on receivables and contract assets (HKD Mn)

———22.2—

Operating income, agg. (HKD Mn)

2.05-33.980.98-19.09-11.35

Operating margin, agg. (%)

0.6-14.20.5-8.9-6.3

Depreciation and amortisation, agg. (HKD Mn)

12.059.8312.2712.8611

EBITDA, agg. (HKD Mn)

14.10-21.2114.68-5.96—

EBITDA margin, agg. (%)

4.1-8.97.6-2.8—

Pre-tax income, agg. (HKD Mn)

3.08-32.720.66-20.55—

Net income attributable (HKD Mn)

2.24-30.040.66-20.55-11.4

Net margin (%)

0.65-12.570.34-9.58-6.36

Basic EPS (HK cents)

0.28-3.750.08-2.57-1.43

Diluted EPS (HK cents)

0.28-3.750.08-2.57-1.43

Dividend per share (HK cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026

Revenue (HKD Mn)

219.3331.1289.2452.6241.0344.3239.0194.0214.5179.3

Gross profit (HKD Mn)

50.053.00.9—19.024.8-6.628.631.013.6

Net income attributable (HKD Mn)

28.015.2-20.5—-0.552.24-30.040.66-20.55-11.4

Balance Sheet and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Total equity attributable (HKD Mn)

107777756.945.5

Bank balances and cash (HKD Mn)

———14.76.4

Bank borrowings (HKD Mn)

———25.02.3

Total debt, company definition (HKD Mn)

———75.041.3

Net debt, company definition (HKD Mn)

———60.334.9

Gearing ratio, total debt / equity (%)

———131.890.8

Short-term debt, agg. Stoxray (HKD Mn)

—27.726.2——

Long-term debt, agg. Stoxray (HKD Mn)

—3.313.2——

Net debt, agg. Stoxray (HKD Mn)

—18.49.6——

Working capital, agg. (HKD Mn)

5936382823

Goodwill and intangibles (HKD Mn)

00000

Pledged machinery NBV (HKD Mn)

———11.99.0

Pledged life-insurance policy (HKD Mn)

———4.24.2

Book value per share (HKD)

0.130.100.100.070.06

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Free cash flow per share, agg. (HKD)

0.02—0.04-0.02—

Dividends paid (HKD Mn)

00000

Share buybacks (HKD Mn)

00000

Equity fund raising (HKD Mn)

00000

Margin Analysis (%) and Income Statement

RatioFY2022FY2023FY2024FY2025FY2026

ROE, agg. (%)

2.12-32.720.85-30.59-22.27

ROIC, agg. (%)

2.27—1.03——

Debt / equity, company gearing (%)

———131.890.8

Revenue per employee (HKD Mn)

——2.902.792.42

Staff cost / revenue (%)

———17.819.9

Admin expense / revenue (%)

———13.214.8

Revenue by Region and Region Margins & Growth (%)

RegionFY2024FY2025FY2026

Hong Kong revenue (HKD Mn)

194.0214.5179.3

Hong Kong growth (%)

-18.810.5-16.4

Mainland China revenue (HKD Mn)

000

Rest of world revenue (HKD Mn)

000

Valuation Snapshot

MetricValueSource / basis

Share price (≈11 Oct 2026)

HK$0.56

ROIC.ai

Market capitalisation

~HK$448M

800M shares × HK$0.56

Earlier 2026 aggregator quote

HK$0.81 (~HK$648M)

ROIC.ai (earlier snapshot)

Last close before Apr 2026 suspension

HK$0.360

Gelonghui

Offer price (Apr–May 2026)

HK$0.2375

FY2026 AR

Apr 2023 block price

HK$0.145

Announcement

IPO indicative range

HK$0.45–0.55

—

Price ~Apr 2025 (aggregator)

~HK$0.05 (market cap ~US$5M)

Stoxray

P/E (FY2026)

Not meaningful (loss)

—

P/B (FY2026 equity HK$45.5M)

~9.8x

Computed

EV (mkt cap + company-defined debt HK$41.3M – cash HK$6.4M)

~HK$483M

Computed

EV/Sales (FY2026)

~2.7x

Computed

Dividend yield

0%

No dividends since listing per available data

Capital Markets

Metric1-Year3-Year5-Year

Total return (%)

302.88330.77278.38

Capital Markets (Annual)

MetricFY2022FY2023FY2024FY2025FY2026

Final dividend per share (HK cents)

00000

Analyst Conclusions

Management guidance

No quantitative guidance. Management expects the industry environment to remain challenging, with a slow private property market, persistently high interest rates, rising construction costs and fierce price competition. It will maintain prudent project selection and cost control, seek additional qualifications, strengthen financial resources, invest in manpower and IT, and pursue public-sector foundation opportunities (FY2026 AR).

Consensus

No consensus estimates exist.

Bull case

  1. Platform optionality: A controller that paid HK$133M in cash and installed its two founders as executive directors likely intends to build or inject a meaningful AI/life-sciences business; HaploX's footprint (CLIA/CAP lab, GMP factory, Illumina partnership, ~700 institutional customers) could transform the listed entity's scale and growth profile.

  2. Self-help in construction: FY2026's revenue decline was partly deliberate credit tightening; with debt largely repaid (bank borrowings HK$2.3M) and admin costs already trimmed, a modest volume recovery at FY2024–FY2025 margins (~14–15%) could restore break-even.

  3. Cyclical recovery: Any easing of Hong Kong interest rates and a pickup in private land sales, combined with access to public works, could lift foundation demand from cyclical lows.

Bear case

  1. Valuation detached from fundamentals: At ~9.8x book and ~2.7x EV/Sales for a loss-making contractor, the share price discounts a pivot that has not been announced and may face HKEX reverse-takeover scrutiny.

  2. Deteriorating core business: Revenue has fallen ~15% p.a. over four years, gross margin halved to 7.6% in FY2026, cash is only HK$6.4M and equity has fallen ~58% since FY2022.

  3. Minority-holder risk: Any asset injection from the controller would be a connected transaction priced by the controller; dilution or unfavourable terms are possible, and the offer's HK$0.2375 price anchors what the controller deemed fair value only months ago.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhy it matters
Nov 2026Interim results for 6M to 30 Sep 2026First results under new control; check revenue run-rate, margins, cash, ECL
Any timeAnnouncements of acquisitions, disposals, connected transactions or VSAsClarifies the AiLife strategy; RTO classification risk
Any timePlacing of new shares or convertible issuesFunding for pivot; dilution
OngoingBoard/management changes (e.g., new CEO from HaploX side, departure of construction team)Signal on future of construction business
Dec 2026Three INEDs reach nine-year tenureIndependence assessment / board refresh
2,027HK interest-rate path and private land salesCore market demand
Mid-2027FY2027 annual results (expected ~June 2027)Full-year view of new strategy

Analyst verdict

AiLife International Group is two stories wrapped in one ticker. The first is a small, long-established Hong Kong foundation contractor — formerly Ling Yui — that has been shrinking and mostly unprofitable since FY2020. Its FY2026 numbers (revenue HK$179.3 million, gross margin 7.6%, net loss HK$11.4 million, cash HK$6.4 million, equity HK$45.5 million) describe a business that is managing decline sensibly — repaying borrowings, tightening credit, trimming overhead — but that lacks scale, pricing power or a visible catalyst for recovery while Hong Kong's private development market remains depressed. On a standalone basis, it would justify a valuation at or below book value, which is roughly HK$0.06 per share.

The second story is the April 2026 change of control. Hapbiotech, a vehicle of Shenzhen genomics group HaploX, paid HK$133 million for 70% of the company, renamed it "AiLife" and installed HaploX's two scientist-founders on the board. The market has responded by valuing the equity at around HK$448 million, nearly ten times book and more than double the HK$0.2375 offer price. That premium is a bet on a future, as-yet-unannounced transformation into an AI-enabled life-sciences platform.

Our assessment is that the construction business is a melting ice cube with limited downside protection from the balance sheet, while the pivot remains plausible but unproven and subject to significant regulatory, valuation and connected-party risk. The equity is therefore best characterised as a speculative special situation rather than an investment underpinned by fundamentals. Investors should demand concrete disclosure — the nature, valuation and funding of any assets to be injected, how minority interests are protected, and the fate of the foundation business — before treating current prices as anything other than option value. Until such disclosure, risk-reward appears skewed to the downside for fundamentals-driven holders.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedAgeBackground / prior rolesEducation

Ling Chi Fai

Executive Director, Chairman; chair of Nomination Committee; member of Remuneration Committee

ED 1 Sep 2022 (with Group since 2000)

63

~46 years in construction; Hang Fai Engineering (1980–97); Ming Lee Engineering project manager (1997); formerly Group GM/project manager; oversees site operations and tendering

—

Leung Cheuk Ho

Executive Director, CEO

29 Sep 2023

35

12+ years civil engineering; Ming Lee Foundation since 2016 (project manager, engineer, director); Rich Team Management (2011–16)

BSc Civil Engineering, Leeds Beckett University (2022); Professional Diploma, HK College of Technology (2020)

Dr. Xu Mingyan

Executive Director

11 May 2026

43

Co-founded HaploX Investment Holding (Sept 2014); executive director there since Feb 2023; previously scientist at Cambrian Genomics (2013–14)

BSc Chemistry, Nanchang University; MSc Inorganic Chemistry, Beijing Normal University; PhD Biomedical Science, University of New Mexico

Dr. Chen Shifu

Executive Director

11 May 2026

41

Co-founded HaploX (Sept 2014); responsible for product R&D and diagnostics development; formerly CUDA technical consultant and senior software engineer at NVIDIA Semiconductor (Shenzhen) (2010–14)

BSc Mathematics, Nanchang University; MSc Computer Software, ICT-CAS; PhD Pattern Recognition, Shenzhen Institute of Advanced Technology (CAS)

Ling Yuk Tong (Tommy)

Non-executive Director; Nomination Committee member

1 Nov 2024

38

IT infrastructure specialist; iCON Business System (2013–15); assistant manager, TÜV Rheinland Hong Kong (since 2015); son of the Chairman

BSc Computing, Southampton Solent; MSc Computer Science, CityU HK; HND Civil Engineering (2021)

Chong Kam Fung

INED; chair of Remuneration Committee

4 Dec 2017

46

HKICPA, FCCA; PwC (2006–13, senior manager); company secretary of Ahsay Backup Software (8290)

BA Accountancy, PolyU

Ho Chun Chung Patrick

INED; chair of Audit Committee

4 Dec 2017

62

HKICPA, FCCA; PwC (1987–91); financial controller Gold Peak and Chen Hsong; INED of A & S Group (1737) and Realord Group (1196)

Prof. Diploma Accountancy, HK Polytechnic; MSc Finance, CityU HK

Shi Wai Lim William

INED

4 Dec 2017

48

28+ years construction; Chartered Building Engineer; director of Unibright Construction; former ED of GoldFinance Holdings (1462, delisted 2021)

Multiple professional qualifications

Yau Suk Man

INED

1 Nov 2024

48

26+ years in construction cost control; Gammon Skanska, Wheelock, COLI, Chun Wo, Fosun Property, Top Spring, Easyknit; contracts manager at Hip Shing Hong since 2023

BSc Quantity Surveying, CityU HK; two MSc degrees, PolyU; MRICS

“—” = not publicly disclosed.

Executive Leadership Team

NameRoleAgeNotes

Wong Chi Wai (Karl)

Chief Financial Officer (since 1 Jan 2018)

40

Ex-HLB Hodgson Impey Cheng (2011–15) — the Group's current audit firm; Coface Greater China (2015–16)

Tsang Kwok Ping

Construction Manager

54

~36 years in construction; with Group since 2000

Lo Hin Chi

Director of Ming Lee Engineering; authorised signatory (Foundation)

35

Chartered Civil Engineer; ex-Paul Y. Management and China Overseas

Ng Hoi Ying

Company Secretary (outsourced)

39

HKICPA; ex-Deloitte; secretary to seven HK-listed companies

Board & Management Changes

DateChangeContext

1 Sep 2022

Ling Chi Fai appointed ED and Chairman

Founder-operator returns to board leadership

29 Sep 2023

CEO Chan Siu Hung resigns (personal commitments); Leung Cheuk Ho appointed ED/CEO

Generational transition to an internal engineer

1 Nov 2024

Ling Yuk Tong (NED) and Yau Suk Man (INED) appointed

Follows Reach Goal offer in 2024

11 May 2026

Dr. Xu Mingyan and Dr. Chen Shifu appointed EDs

Nominees of new controller Hapbiotech/HaploX

Major Shareholders

HolderShares% of issuedSource

Hapbiotech Investment Holding Limited (HaploX)

560,140,000 + 90,000 offer acceptances

~70.03

FY2026 AR

Public / other shareholders

~239,770,000

~29.97

Derived

Total

800,000,000100

FY2026 AR

Competitive Landscape

Key Competitors

CompetitorListingSegment overlapRelative positioning

Chinney Kin Wing (Chinney Alliance Group)

HKEX 0385 (parent)

Piling and foundation

Large, long-established foundation specialist with public-works track record

Build King Holdings

HKEX 0240

Civil engineering, foundation

Much larger, public-infrastructure oriented

Asia Allied Infrastructure (Chun Wo)

HKEX 0711

Civil, foundation, building

Diversified contractor

Shun Wo Group Holdings

HKEX 1591

Foundation works

Small-cap peer

Royal Deluxe Holdings

HKEX 3789

Foundation/ELS and machinery

Small-cap peer

Wan Kei Group Holdings

HKEX 1718

Foundation works

Small-cap peer

Sang Hing Holdings

HKEX 1472

Site formation and civil works

Small-cap peer

Boill Healthcare Holdings (formerly Ngai Shun Holdings)

HKEX 1246

Piling (historical)

Former piling peer that pivoted to healthcare — a precedent for Ling Yui's own possible pivot

Gammon Construction

Private (JV)

Foundation, civil, building

Tier-1 contractor and potential customer/competitor

Bachy Soletanche Group

Private

Specialist geotechnical/foundation

International specialist

Competitor Detail

MetricLing Yui / AiLife (FY2026)

Revenue (HKD Mn)

179.3

Revenue growth (%)

-16.4

Gross margin (%)

7.6

Net margin (%)

-6.4

R&D intensity (%)

0

Company Snapshot

$23M

Revenue

74

Employees

2000

Founded

Windward, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Deep operating experience: The chairman has ~46 years in construction and the construction manager ~36 years, both with the Group since 2000 (FY2026 AR).
  • Main-contractor capability: Ming Lee Engineering holds an authorised-signatory registration in the Foundation category via Chartered Civil Engineer Lo Hin Chi (FY2026 AR).
  • Deleveraging achieved: Bank borrowings cut from HK$25.0M to HK$2.3M and gearing from 131.8% to 90.8% in FY2026 (FY2026 AR).
  • Clean compliance record: No material breach of laws and regulations reported in FY2026; no material contingent liabilities (FY2026 AR).
  • Owned equipment fleet: Machinery generated rental income in FY2026, contributing to other income rising to HK$3.8M from HK$0.7M (FY2026 AR).
  • Well-capitalised new controller: Hapbiotech paid HK$133.0M in cash for 70.02%, demonstrating financial capacity at the parent level (FY2026 AR).

Weaknesses

  • Persistent losses: Net losses in three of the last four years totalling ~HK$61M (FY2023 –30.0, FY2025 –20.5, FY2026 –11.4) against a single HK$0.66M profit in FY2024.
  • Margin volatility: Gross margin ranged from –2.8% (FY2023) to 14.8% (FY2024) to 7.6% (FY2026).
  • Shrinking equity: HK$107M (FY2022) to HK$45.5M (FY2026).
  • Low liquidity: Cash of HK$6.4M at 31 Mar 2026 vs HK$14.7M a year earlier.
  • Customer concentration: Company cites reliance on a few customers with non-recurring contracts (FY2026 AR risk factors).
  • No internal audit function: Deviation from CG Code D.2.5 (FY2026 AR).

Opportunities

  • Public foundation sector: Dedicated project team formed to target prominent clients (FY2026 Chairman's Statement).
  • Life-sciences/AI pivot: Controller HaploX serves ~700 biopharma and research organisations and has an Illumina sequencer partnership (JETRO; GenomeWeb) — a potential source of injected businesses.
  • Interest-rate normalisation: Lower rates would revive private development, the Group's core market (inference from management's attribution of weakness to high rates).
  • Low-carbon construction solutions: ESG report identifies developing low-carbon foundation solutions and modernising the fleet.
  • Treasury-share and hybrid-meeting flexibility: New M&A (Aug 2025) provides capital-management tools.
  • Shell value realisation: Market price (~HK$0.56) far above book (~HK$0.06) implies investors ascribe value to the listing platform.

Threats

  • Price war: Management expects fierce pricing competition in private foundations (FY2026 AR).
  • Counterparty defaults: FY2025 ECL of HK$22.2M (~10% of revenue) could recur.
  • Regulatory hurdles for asset injection: HKEX reverse-takeover and suitability rules could block or delay a pivot.
  • Cost overruns: Estimation risk on fixed-price tenders (FY2026 AR principal risk #3); FY2023 gross loss shows materialisation.
  • Subcontractor non-performance: Group bears responsibility (FY2026 AR principal risk #2).
  • Climate/physical risk: Typhoons, flooding, landslides and heat stress can suspend sites (FY2026 ESG report).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
24 Mar 2025Yau Suk Man and Ling Yuk Tong added to board committeesCommittee refresh
26 Jun 2025FY2025 annual results: revenue +10.5% to HK$214.5M; loss HK$20.5M; ECL HK$22.2M; no dividendCredit risk crystallises
26 Jun 2025Workforce Diversity Policy adopted; Nomination Committee terms revisedGovernance housekeeping
21 Jul 2025FY2025 Annual Report and AGM circular publishedFiling
28 Aug 2025AGM: all resolutions passed, incl. new M&AEnables hybrid meetings and treasury shares
1 Sep 2025Chairman Ling's service contract renewed for 3 yearsContinuity
Nov 2025Board meeting notice for interim results (meeting 14 Nov 2025)Routine
14 Nov 2025Interim results for six months to 30 Sep 2025 announcedRevenue weakened in H2 per later commentary
Dec 2025Interim report publishedFiling
30 Jan 2026Hapbiotech Investment Holding incorporated (BVI)Acquisition vehicle formed
1 Apr 2026SPA for 70.02% signed; shares suspended pending announcementChange of control
9 Apr 2026Completion of SPA; HK$133.0M paid in fullControl passes to HaploX
14 Apr 2026Joint announcement of MGO at HK$0.2375; proposed rename to AiLifeStrategic signal
15 Apr 2026Trading resumesPrice re-rates
5 May 2026Composite offer document despatchedOffer timetable
11 May 2026Dr. Xu Mingyan and Dr. Chen Shifu appointed EDsController representation
26 May 2026Offer closes; acceptances 90,000 sharesController ends at ~70.03%
27 May 2026Results-of-offer announcementPublic float confirmed adequate
2 Jun 2026EGM circular for name changeFiling
18 Jun 2026EGM approves name changeRebrand approved
29 Jun 2026FY2026 annual results: revenue –16.4% to HK$179.3M; loss HK$11.4M; GPM 7.6%; no dividendOperating weakness persists
17 Jul 2026FY2026 Annual Report published (incl. expanded climate disclosures)Filing
30 Jul 2026Change of company name effective; new stock short name announcedLegal rename complete
4 Aug 2026Trading as "AILIFE INTL" beginsMarket identity changes
31 Aug 2026AGM (scheduled) — re-election of Xu, Chen, Leung, Chong, Shi–
Nov 2026 (expected)Interim results for six months to 30 Sep 2026Next key data point

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue fell from HKD 344.3 Mn in FY2022 to HKD 179.3 Mn in FY2026.
AiLife International Group Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue344.3239194214.5179.3
Gross profit24.8-6.628.63113.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.